NVDAMillionaire
Posted - 1 day ago
$INTS Intensity Therapeutics (NASDAQ:INTS): Building a Formidable Pipeline to Tackle Solid Tumors https://beyondspx.com/article/intensity-therapeutics-nasdaqints-building-a-formidable-pipeline-to-tackle-solid-tumors
OpenOutcrier
Posted - 11/21/24
$INTS (-5.1% pre) Intensity Therapeutics (INTS) Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - SI https://ooc.bz/l/48947
Stmkr
Posted - 11/21/24
$INTS Has the company discussed how it plans to fung ongoing/planned trials??
Stmkr
Posted - 11/21/24
$INTS Just 3M?? Less even than the operating expenses of a single quarter
donutfish
Posted - 11/17/24
$INTS Anyone see the CTOS presentation they did?
Powderranger
Posted - 11/14/24
$INTS sleeping giant
IN0V8
Posted - 10/31/24
$INTS Watch H.C. Wainwright initiates coverage with buy rating H.C. Wainwright initiates coverage with target $5
Thestocktraderhubzee
Posted - 10/31/24
$INTS Intensity Therapeutics And The Swiss Group For Clinical Cancer Research SAKK Dosed First Patient In Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial
Ianwalsh15
Posted - 10/21/24
$INTS
UPupANDaway2020
Posted - 09/11/24
$INTS log in and register…listen to the audio!
Going to Phase 3 Trial.
https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6
justiceforb_85
Posted - 08/23/24
$INTS $XBI hoping for positive news on trial for soft tissue sarcoma and TNBC.
ReadyMate
Posted - 08/23/24
$PRTG $INTS $BHVN That should have read ‘sad’ instead of ‘sas’
TheDarkPrince
Posted - 08/15/24
@HedgeTrade SoftBank pulled out of the deal because INTC is incompetent. .
Stock_Titan
Posted - 08/08/24
$INTS Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/INTS/intensity-therapeutics-reports-second-quarter-2024-financial-results-aifq60sijw7s.html
Chieftess
Posted - 4 months ago
$INTS Think its time to take a starter here - maybe I get some on sale tomorrow ;) Good Luck Bulls!
NVDAMillionaire
Posted - 4 months ago
$INTS INTS: Intensity Therapeutics Poised for Breakthrough in Cancer Treatment http://beyondspx.com/2024/08/02/ints-intensity-therapeutics-poised-for-breakthrough-in-cancer-treatment/
NVDAMillionaire
Posted - 07/12/24
$INTS Intensity Therapeutics, Inc. (NASDAQ:INTS): Pioneering a Novel Approach to Cancer Treatment http://beyondspx.com/2024/07/11/intensity-therapeutics-inc-nasdaqints-pioneering-a-novel-approach-to-cancer-treatment/
Stock_Titan
Posted - 07/09/24
$INTS Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
https://www.stocktitan.net/news/INTS/intensity-therapeutics-inc-announces-first-patient-dosed-in-its-01j9r2tgz5cj.html
DonCorleone77
Posted - 5 months ago
$INTS Intensity Therapeutics files to sell 394.5K shares of common stock for holders
DonCorleone77
Posted - 5 months ago
$INTS Intensity Therapeutics files $150M mixed securities shelf
JSTJ
Posted - 06/21/24
$INTS Rough end of the week 🥴
Tjcmd
Posted - 05/19/24
$INTS So Novo bought Emisphere for the technology will INTS need a licensing agreement with Novo?
Carl_K
Posted - 05/16/24
$AGEN $INTS may be one to look into. "Data from that same trial presented at CTOS in November 2023 and ASCO 2023 in June 2023 showed a disease control rate of 93% for subjects on INT230-6 alone, and median overall survival of 21.5 months. Disease control rate measures the percentage of patients who have achieved stable disease, partial response or complete response.
In comparison, Agenus' (AGEN) combination therapy of immune-activating botensilimab and anti-PD-1 checkpoint inhibitor balstilimab, looked at as a very interesting drug candidate for a multitude of solid tumors, has a disease control rate of 63% in a Phase 1b trial, with a median of three prior lines of therapy. INT230-6's 93% disease control rate is well above that, for the same indication."
https://seekingalpha.com/article/4693038-intensity-therapeutics-a-bargain-for-a-late-stage-company-with-a-remarkable-oncology-drug
jvitalis
Posted - 05/14/24
$INTS The final nail on the coffin will be the Chinese government tariffs on Tesla. Key top managers are abandoning the sinking ship and Tesla is desperately hanging on with lies, smokescreens, and mirrors. Compared to last quarter: EPS down 85.2%, Revenues down 15.4%, Operating Margins down 33% and Free Cash Flow down 223%!!! The same goes for Trailing Twelve Months year over year, all above indicators are down from -2% to -68%! In general production, profit margins, and revenues are declining and FSD lawsuits as well as expenses are going up. The competition has caught up and the profit margins will continue to shrink. This is no longer a growth stock and should be priced like GM and Ford at 5-15x Price to Earnings and not at 45x, which means the stock price should be between $20-$60.
ButterCapital
Posted - 05/13/24
$INTS 👀
jvitalis
Posted - 05/10/24
$INTS Corporate Update In mid-2024, the Company intends on initiating a Phase 3 open-label, randomized study, or the INVINCIBLE-3 Study, testing INT230-6 as a monotherapy compared to the standard of care ("SOC") drugs in second and third line treatment for certain soft tissue sarcoma subtypes. We plan to enroll 333 patients with an endpoint of overall survival and have screened and qualified over 30 sites for the INVINCIBLE-3 Study. In mid-2024, the Company intends on initiating a Phase 2/3 program testing INT230-6 in combination with the SOC treatment (chemotherapy/immunotherapy) compared to SOC alone in women with triple negative breast cancer in presurgical (neoadjuvant) breast cancer. The endpoint for the Phase 2 portion of the study, or the INVINCIBLE-4 Study, is the change in the pathological complete response rate for the combination compared to the SOC alone. We expect to initiate the INVINCIBLE-4 Study in mid-2024, which will provide data to size a Phase 3 study.